Fempro 2.5mg Tablet

Most side effects of the Fempro 2.5 mg tablet do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.

• Headaches
• Heartburn
• Muscle or joint pain
• Vaginal bleeding 
• Shortness of breath
• Yellowing of skin or eyes
• Nausea
• Vomiting

​Fempro 2.5 mg tablets are a prescription-based medication that is taken orally with or without a meal as advised by the doctor.

In case of an overdose of Fempro tablets, contact your doctor or any healthcare provider and seek medical attention immediately.

The CYP19A1 enzyme is blocked by the non-steroidal competitive aromatase inhibitor Fempro. As a result, the production of estrogen from androgens is stopped.

The cancers that rely on estrogen, a natural female hormone, decrease in number as its levels decline.

Some breast tumors that require estrogen to grow are less likely to spread when taken with these medications.

If you forget to take a dose of Fempro 2.5 mg tablet consult your doctor. Don’t double up the next dose to cope with the missed one unless your doctor recommends it.​

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Fjermeros, K., Ghannoum, S., Geisler, S. B., Bhargava, S., Tahiri, A., Klajic, J., Geisler, J. (2024). The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer. Future Oncology, 20(32), 2457–2466 - https://pubmed.ncbi.nlm.nih.gov/39073142/

Konstantinopoulos, P. A., et al. (2025). Treatment of recurrent endometrial cancer with metformin, letrozole, and abemaciclib is safe and promising. Presented at the Society of Gynecologic Oncology Annual Meeting, Seattle - https://www.dana-farber.org/newsroom/news-releases/2025/treatment-of-recurrent-endometrial-cancer-with-metformin-letrozole-and-abemaciclib-is-safe-and-promising-dana-farber-research-shows

Lin, J., Wu, F., Wang, B., et al. (2024). Impact of letrozole co‑treatment in an antagonist protocol for IVF/ICSI: A retrospective study. Reproductive Biology and Endocrinology, 22, 126 - https://pubmed.ncbi.nlm.nih.gov/39415184/

Mirza, M. R., Bjørge, L., Marmé, F., et al. (2025). Palbociclib plus letrozole in estrogen receptor‑positive advanced/recurrent endometrial cancer: double‑blind placebo‑controlled randomized phase II ENGOT‑EN3/PALEO trial. Gynecologic Oncology, 192, 128–136 - https://pubmed.ncbi.nlm.nih.gov/39657575/

Xie, Y., Li, P., Hao, G. et al. (2025).  Letrozole ovulation Regimen for frozen-thawed embryo transfer in women with polycystic ovary syndrome: a multi-centre randomised controlled trial. Reprod Biol Endocrinol 23, 103.